Juan Alonso - Genomma Lab Independent Director

LABB Stock  MXN 26.29  0.27  1.04%   

Director

Mr. Juan Alonso serves as Independent Director of Genomma Lab Internacional, S.A.B. de C.V. He was serving as Chief Executive Officer of ZAO Future Technologies and Chairman of Domino Pizza Jalisco SA de CV. In March 2007, he holds a partnership agreement with Israel BSG Investments, the developer of real estate in Russia and the Commonwealth of Independent States, to develop nearly one million square meters of residential and commercial real estate in Russia. He is also the majority shareholder of ZAO SILVER Nizhny Novgorod, the national water bottler Nestle in Russia. Previously, he was President of Domino Pizza Jalisco, SA de CV, Master franchisee of Domino Pizza in central Mexico, as well as the majority shareholder of Baskin Robbins DF.
Age 52
Phone52 55 5081 0000
Webhttps://www.genommalab.com

Genomma Lab Management Efficiency

The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.
Genomma Lab Internacional has accumulated 3.83 B in total debt with debt to equity ratio (D/E) of 0.61, which is about average as compared to similar companies. Genomma Lab Internacional has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Genomma Lab until it has trouble settling it off, either with new capital or with free cash flow. So, Genomma Lab's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomma Lab Internacional sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomma to invest in growth at high rates of return. When we think about Genomma Lab's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Jesus LaporteKimberly Clark de Mxico
52
Luiz RodriguesKimberly Clark de Mxico
N/A
Fernando SahagunGrupo Mxico SAB
N/A
Antonio RuizGrupo Mxico SAB
N/A
Alfonso NoriegaGrupo Financiero Banorte
57
Guillermo HinojosaAlfa SAB de
68
Michael HsuKimberly Clark de Mxico
54
Prudencio MartinezGrupo Mxico SAB
N/A
Thomas RodriguezGrupo Financiero Banorte
64
Rolando SaenzGrupo Mxico SAB
N/A
Juan MorenoGrupo Financiero Banorte
61
Enrique MejoradaAlfa SAB de
62
Javier GomezGruma SAB de
77
Carlos CurielKimberly Clark de Mxico
N/A
Thomas RodriguezGruma SAB de
64
Hector DahlGrupo Financiero Banorte
71
Jose EguiaGrupo Financiero Banorte
51
Antonio BrachoGrupo Mxico SAB
N/A
Ernesto DiazKimberly Clark de Mxico
N/A
Adrian CuevaGrupo Financiero Banorte
44
Jose RojasAlfa SAB de
64
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico, the United States, and Latin America. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico. GENOMMA LAB operates under Drug ManufacturersSpecialty Generic classification in Mexico and is traded on Mexico Stock Exchange. It employs 1451 people. Genomma Lab Internacional (LABB) is traded on Mexican Exchange in Mexico and employs 2,297 people.

Management Performance

Genomma Lab Internacional Leadership Team

Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott Emerson, Independent Director
Cesar Lopez, Vice President of Global Marketing
Efran Crdova, Deputy Sec
Carlos Alonso, Independent Director
Marianne Velasco, Global HR
Jorge Munoz, Independent Director
Ignacio Rodriguez, Independent Director
Alejandro Patino, Executive Vice President of Human Capital and Commercial Expansion
L Porres, Legal Officer
Rodrigo Aspra, Chairman of the Board, Independent Director
Juan Gavito, Independent Director
Antonio Galland, Executive Vice President, Chief Financial and Chief Administrative Officer
Hector Gonzalez, Independent Director
Burkhard Wittek, Director
Alejandro Patio, Media, Relations
Javier Castilla, Independent Director
Engineer Galland, Exec CFO
Sabrina Aspra, Director of International Operations, Director
Mximo Juda, Advisor
Daniel Neria, Head Relations
Juan Alonso, Independent Director
Santiago Pelaez, Vice President of Industrial and Research and Development
Jorge Valderrama, Chief Executive Officer
Juan Sparvieri, Chief Operating Officer, Vice President
Leticia Herrera, Global Director of Human Resources (Genomma Experience)

Genomma Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Genomma Stock Analysis

When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.